Skip to main content

Table 1 Clinical characteristics of patients in the NGS and in the PCR cohort. In the NGS cohort 10 patients had Gleason score 7a (3 + 4) and 10 patients had Gleason score 7b (4 + 3), and 13 and 7 patients were classified as intermediate and aggressive risk, respectively, using the D’Amico Risk Classification

From: Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes

  

Discovery cohort (RNA-seq)

Validation cohort (RT-qPCR)

 

Control

Patient

Control

Patient

Number

 

9

20

19

28

Age (median, years)

 

58

66

56

67

Gleason Scorea

 

nd

 

nd

 
 

7

 

20

 

21

 

8–10

   

7

Clinical T-stagingb

 

nd

 

nd

 
 

T1

 

11

 

12

 

T2

 

6

 

9

 

T3

 

3

 

7

PSAb (ng/mL)

 

nd

8.8

nd

13.5

  1. Nd non determined
  2. aGleason Score in biopsy tissue. bClinical T-staging and PSA levels (ng/mL) at time of diagnosis